Viralytics cancer trials show strong results

Company News


Viralytics Limited (ASX:VLA) says preclinical data from its CAVATAK treatment coupled with a check point inhibitor is showing strong results in melanoma and lung cancer studies. 
 
The pharmaceutical company says mice with lung cancer and melanoma show significant survival benefits with five out of eight mice alive after 47 days compared to just one out of eight surviving after being treated with just one of the medicines. 
 
Viralytics says the results support current trial evaluations and it will continue assessing the promising treatments. Plans to test them on advanced melanoma patients are now in the final stages.  
 
Viralytics reported a net loss of $6.06 million for the six month to end of December 2015. 

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?